Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2011 by Oxford University Press. All rights reserved. This chapter covers interventional studies aimed at lowering the incidence of cardiovascular disease (CVD), nephropathy, retinopathy, blindness, lower-extremity amputation (LEA), peripheral sensory neuropathy, and autonomic neuropathy; and at prolonging life. It includes studies that address clinical endpoints. It shows that individuals with diabetes and their providers of care can reduce the occurrence of diabetic complications by lowering glucose, blood pressure, and LDL, either alone or in combination. Nonpharmacologic interventions, chiefly those related to retinopathy and obesity, also improve outcomes. To date evidence for lowering blood glucose and blood pressure does not support the use of specific agents except possibly metformin and blockade of the angiotensin system. For LDL, statins remain the intervention of choice.

Original publication





Book title

Diabetes Public Health: From Data to Policy

Publication Date